MUMBAI (Reuters) - Cipla Ltd, India's third-largest drugmaker by sales, reported a second-quarter net profit slightly below analysts estimates, as expenses rose.
Net profit rose 44 percent to 4.31 billion rupees ($65.56 million) in the quarter ended September, Cipla said in a statement on Thursday. But it was below analysts' average estimate of 4.84 billion rupees, according to Thomson Reuters data.
Cipla, whose biggest market is India, is now working on expanding its footprint in the United States, where many of its peers have been selling for years.
The company agreed to buy two generics businesses in cash deals worth $550 million in September, gaining drugs to treat infection, diabetes and central nervous system disorders.
($1 = 65.7400 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app